The Michigan Program on Value Enhancement (MPrOVE) hosts monthly Innovation to Implementation (i2i) Lab gatherings with IHPI members to discuss opportunities for developing, enhancing, or disseminating research projects that align with Michigan Medicine needs.
About this i2i Lab
After collaborating on the ‘Measuring low-value care in [US] Medicare’ project (JAMA Intern Med. 2014 Jul;174(7)), Dr. Elshaug went on to further develop and expand the method across Australia’s hybrid public/private health care system. Today, his team has analysed the prevalence, trends and costs, etc. of a small set of low-value practices for almost 85% of its 26 million population.
This seminar will cover three interrelated aspects of that work:
- Overview of results from the almost nation-wide low-value care analyses, including jurisdiction and payer type (e.g. public or private) comparisons, physician variability within hospitals, physician variability between hospitals, and hospital acquired complications arising from low-value care.
- How payers have adopted the measurement algorithms into their surveillance systems, with comprehensive dashboards used for targeted audit and feedback to districts (networks), individual hospitals, departments and physicians.
- The COVID-19 response in Australia has reduced (and in some cases, eliminated) the use of low-value procedures. Health departments are grasping the opportunity to learn from this enforced break so that after the pandemic, we can reassess and reorient needed capacity to only high-value care. Can this be achieved?
About the Presenter
Adam Elshaug, Ph.D., M.P.H., is a visiting fellow with the USC-Brookings Schaeffer Initiative for Health Policy at The Brookings Institution in Washington D.C. In Australia, he is a professor of health policy and was recently appointed director of the Centre for Health Policy at The University of Melbourne, with joint chair appointments across the Schools of Medicine and Population and Global Health.
Dr. Elshaug leads an international program of work specializing in measuring and reducing low-value care and optimizing value in health care. He practices an applied policy approach with approximately half of his time spent working directly with payer and provider organizations. For example, he is a ministerial appointee to the Medicare Benefits Schedule (MBS) Review Taskforce, which is undertaking a 5+ year review process of Australia’s entire Medicare fee-for-service system utilising health technology assessment principles and processes. Dr. Elshaug sits on the Board of Directors of the New South Wales Bureau of Health Information (BHI), an arms-length government agency that publicly reports on the performance of all public hospitals. He is also principal economics and policy advisor to Cancer Australia, Australia’s peak Cancer organization.